Vaxart (NASDAQ:VXRT) posted its quarterly earnings data on Sunday. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04), Briefing.com reports. The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.62 million. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. The company’s revenue was down 82.8% compared to the same quarter last year.
NASDAQ VXRT traded up $0.73 during trading on Tuesday, reaching $8.75. 1,307,073 shares of the company traded hands, compared to its average volume of 18,688,678. The stock’s 50 day moving average price is $6.40 and its two-hundred day moving average price is $6.87. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -15.19 and a beta of -0.11. Vaxart has a 1-year low of $2.23 and a 1-year high of $24.90.
VXRT has been the topic of several research reports. B. Riley restated a “buy” rating and set a $13.00 price target (down from $16.00) on shares of Vaxart in a research note on Thursday, March 4th. Zacks Investment Research lowered Vaxart from a “hold” rating to a “sell” rating in a research note on Tuesday, March 9th.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.
Recommended Story: The components of the Stochastic Momentum Index
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.